Patents by Inventor Kevin R. Campos

Kevin R. Campos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220228184
    Abstract: The present invention relates to an enzymatic synthesis of 4?-ethynyl-2?-deoxy nucleosides and analogs thereof, for example EFdA, that eliminates the use of protecting groups on the intermediates, improves the stereoselectivity of glycosylation and reduces the number of process steps needed to make said compounds. It also relates to the novel intermediates employed in the process.
    Type: Application
    Filed: July 2, 2019
    Publication date: July 21, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Mark A. Huffman, Anna Fryszkowska, Joshua N. Kolev, Paul N. Devine, Kevin R. Campos, Matthew Truppo, Christopher C. Nawrat
  • Patent number: 10618926
    Abstract: The present invention is directed to process for making Compounds of Formula (II): (II), and salts thereof, wherein B, X, R2, R3, R4 R7, R8 and R9 are defined herein.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: April 14, 2020
    Assignee: Merck Sharp & Dohme
    Inventors: Steven M. Silverman, Bryon Ladd Simmons, Zhuqing Liu, Jing Liao, Artis Klapars, Kevin R. Campos, Ana Inés Bellomo Peraza
  • Patent number: 10457690
    Abstract: The present invention is directed to processes for preparing Substituted Tetracyclic Heterocycle Compounds of formula (I): (I) which may be useful as HCV NS5A inhibitors. The present invention is also directed to compounds that may be useful as synthetic intermediates and catalysts in the processes of the invention.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: October 29, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jingjun Yin, Tetsuji Itoh, Jianguo Yin, Bangping Xiang, Kevin R. Campos, Alexei Kalinin, Zhuqing Liu, Melodie Deniz Christensen, Kevin M. Belyk, Richard J. Varsolona, Andrew Brunskill
  • Patent number: 10251903
    Abstract: The present invention is directed to a process for making Nucleoside Phosphoramidate Compounds of formula (I): which are useful for the treatment and prophylaxis of HCV infection. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: April 9, 2019
    Assignees: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLC
    Inventors: Bryon L. Simmons, Kevin R. Campos, Artis Klapars, Alistair J. Stewart, Benjamin A. Mayes, Peter E. Maligres, Alan Hyde, Steven Mark Silverman, Yong-Li Zhong, Adel M. Moussa, Kenneth Baker, Kara Van Valkenburg
  • Patent number: 10202401
    Abstract: The present invention is directed to a process for making Tetracyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2 and R3 are defined above herein. The present invention is also directed to compounds that may be useful as synthetic intermediates in the process of the invention.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: February 12, 2019
    Assignees: MSD R&D CN CO., LTD, MERCK SHARP & DOHME CORP., MERCK SHARP & DOHME LIMITED
    Inventors: Hongming Li, Jingjun Yin, Kevin M. Belyk, Kevin R. Campos, Qinghao Chen, Alan M. Hyde, Tetsuji Itoh, Artis Klapars, Matthew Thomas Tudge, Edward Cleator, Aaron M. Dumas, Louis-Charles Campeau, Yonggang Chen, Ji Qi, Wensong Xiao
  • Patent number: 10053460
    Abstract: The present invention relates to processes for preparing compounds of Formula I. Such compounds include interme-diates in the manufacture of 7-oxo-1,6-diazabicyclo[3.2.1 ]octane-2-carboxamide beta-lactamase inhibitors such as (2S,5R)-7-oxo-N-5 piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide. The present invention also relates to novel intermediates formed i these processes. The present invention relates to a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: August 21, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Zhijian Liu, Nobuyoshi Yasuda, Lu Yang, Artis Klapars, Kevin R. Campos, Mikhail Reibarkh
  • Publication number: 20180179223
    Abstract: The present invention is directed to processes for preparing Substituted Tetracyclic Heterocycle Compounds of formula (I): (I) which may be useful as HCV NS5A inhibitors. The present invention is also directed to compounds that may be useful as synthetic intermediates and catalysts in the processes of the invention.
    Type: Application
    Filed: June 3, 2016
    Publication date: June 28, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Jingjun Yin, Tetsuji Itoh, Jianguo Yin, Bangping Xiang, Kevin R. Campos, Alexei Kalinin, Zhuqing Liu, Melodie Deniz Christensen, Kevin M. Belyk, Richard J. Varsolona, Andrew Brunskill
  • Publication number: 20180111954
    Abstract: The present invention is directed to process for making Compounds of Formula (II): (II), and salts thereof, wherein B, X, R2, R3, R4 R7, R8 and R9 are defined herein.
    Type: Application
    Filed: March 28, 2016
    Publication date: April 26, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Steven M. Silverman, Bryon Ladd Simmons, Zhuqing Liu, Jing Liao, Artis Klapars, Kevin R. Campos, Ana Inés Bellomo Peraza
  • Publication number: 20180065985
    Abstract: The present invention is directed to a process for making Tetracyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2 and R3 are defined above herein. The present invention is also directed to compounds that may be useful as synthetic intermediates in the process of the invention.
    Type: Application
    Filed: November 9, 2017
    Publication date: March 8, 2018
    Applicants: Merck Sharpe & Dohme Corp., MSD R&D (China) Co., Ltd., Merck Sharp & Dohme Limited
    Inventors: Hongming Li, Jingjun Yin, Kevin M. Belyk, Kevin R. Campos, Qinghao Chen, Alan M. Hyde, Tetsuji Itoh, Artis Klapars, Matthew Thomas Tudge, Edward Cleator, Aaron M. Dumas, Louis-Charles Campeau, Yonggang Chen, Ji Qi, Wensong Xiao
  • Publication number: 20170362233
    Abstract: The present invention relates to processes for preparing compounds of Formula I. Such compounds include intermediates in the manufacture of 7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide beta-lactamase inhibitors such as (2S,5R)-7-oxo-N-5 piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide. The present invention also relates to novel intermediates formed i these processes. The present invention relates to a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 30, 2015
    Publication date: December 21, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Zhijian Liu, Nobuyoshi Yasuda, Lu Yang, Artis Klapars, Kevin R. Campos, Mikhail Reibarkh
  • Publication number: 20170246198
    Abstract: The present invention is directed to a process for making Nucleoside Phosphoramidate Compounds of formula (I): which are useful for the treatment and prophylaxis of HCV infection. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).
    Type: Application
    Filed: October 20, 2015
    Publication date: August 31, 2017
    Applicants: IDENIX Pharmaceuticals LLC, Merck Sharp & Dohme Corp.
    Inventors: Bryon L. SIMMONS, Kevin R. CAMPOS, Artis KLAPARS, Alistair J. STEWART, Benjamin A. MAYES, Peter E. MALIGRES, Alan HYDE, Steven Mark SILVERMAN, Yong-Li ZHONG, Adel M. MOUSSA, Kenneth BAKER, Kara van VALKENBURG
  • Publication number: 20170166586
    Abstract: The present invention is directed to a process for making Tetracyclic Heterocycle Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2 and R3 are defined above herein. The present invention is also directed to compounds that are useful as synthetic intermediates in the process of the invention.
    Type: Application
    Filed: July 10, 2015
    Publication date: June 15, 2017
    Inventors: Hongming Li, Jingjun Yin, Kevin M. Belyk, Kevin R. Campos, Qinghao Chen, Alan M. Hyde, Tetsuji Itoh, Artis Klapars, Matthew Thomas Tudge, Edward Cleator, Aaron M. Dumas, Louis-Charles Campeau, Yonggang Chen, Ji Qi, Wensong Xiao
  • Publication number: 20100292282
    Abstract: The present invention relates to a process for producing crystalline 3-[(1S)-1-(1-{(S)-(4-chlorophenyl)[3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl]methyl}azetidin-3-yl)-2-fluoro-2-methyl-propyl]-5-fluorobenzonitrile, and novel salts, solvates, hydrates and polymorphs thereof.
    Type: Application
    Filed: October 20, 2008
    Publication date: November 18, 2010
    Inventors: Kevin R. Campos, Cheng-Yi Chen, Jennifer R. Foley, Michael Hillier, Wendy S. Jen, Amude M. Kassim, Artis Klapars, Andrey V. Peresypkin, Thorsten Rosner, Cecile G. Savarin, Matthew Tudge, Narayan Variankaval, Vicky Vydra, Dalian Zhao
  • Publication number: 20100041893
    Abstract: The present invention is directed to a practical process for the preparation of an enamide (II) by palladium catalyzed coupling of a primary amide (IV) with a compound of structural formula (III), as shown below: As well as to crystalline forms of a compound produced by this process, in particular, an anhydrous crystal form, Form B, and crystalline solvates falling into three patterns, Type 1, Type 2, and Type 3, and crystalline intermediate compounds produced in the process. Still further, the present invention relates to the stereoselective reduction of the tetrasubstituted enamide (II) to the corresponding amide (I).
    Type: Application
    Filed: October 22, 2009
    Publication date: February 18, 2010
    Inventors: KEVIN R. CAMPOS, Artis Klapars, J. Christopher McWilliams, C. Scott Shultz, Debra J. Wallace, Alex M. Chen, Lisa F. Frey, Andrey V. Peresypkin, Yaling Wang, Robert M. Wenslow, Cheng-Yi Chen
  • Patent number: 7629470
    Abstract: The present invention is directed to a practical process for the preparation of an enamide (II) by palladium catalyzed coupling of a primary amide (IV) with a compound of structural formula (III), as shown below: As well as to crystalline forms of a compound produced by this process, in particular, an anhydrous crystal form, Form B, and crystalline solvates falling into three patterns, Type 1, Type 2, and Type 3, and crystalline intermediate compounds produced in the process. Still further, the present invention relates to the stereoselective reduction of the tetrasubstituted enamide (II) to the corresponding amide (I).
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: December 8, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Kevin R. Campos, Artis Klapars, J. Christopher McWilliams, C. Scott Shultz, Debra J. Wallace, Alex M. Chen, Lisa F. Frey, Andrey V. Peresypkin, Yaling Wang, Robert M. Wenslow, Cheng-Yi Chen
  • Publication number: 20090247770
    Abstract: The present invention is directed to a process for preparing ?,? disubstituted ?-lactam derivatives of formula (I) that are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The compounds are useful in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.
    Type: Application
    Filed: August 3, 2007
    Publication date: October 1, 2009
    Inventors: Kevin R. Campos, Cheng Chen, Hideaki Ishibashi, Shinji Kato, Artis Klapars, Yoshinori Kohmura, David J. Pollard, Akihiro Takezawa, Jacob H. Waldman, Debra Wallace, Nobuyoshi Yasuda
  • Publication number: 20090018340
    Abstract: The present invention is directed to a practical process for the preparation of an enamide (II) by palladium catalyzed coupling of a primary amide (IV) with a compound of structural formula (III), as shown below: As well as to crystalline forms of a compound produced by this process, in particular, an anhydrous crystal form, Form B, and crystalline solvates falling into three patterns, Type 1, Type 2, and Type 3, and crystalline intermediate compounds produced in the process. Still further, the present invention relates to the stereoselective reduction of the tetrasubstituted enamide (II) to the corresponding amide (I).
    Type: Application
    Filed: July 1, 2005
    Publication date: January 15, 2009
    Inventors: Kevin R. Campos, Artis Klapars, J. Christopher McWilliams, C. Scott Shultz, Debra J. Wallace, Alex M. Chen, Lisa F. Frey, Andrey V. Peresypkin, Yaling Wang, Robert M. Wenslow, Cheng-Yi Chen